Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone

Annals of Hematology

Volumn 83, Issue 9, 2004, Pages 588-591

  Corso, A ^a   Lorenzi, A ^a   Terulla, V ^b   Airo F ^b   Varettoni, M ^a   Mangiacavalli, S ^a   Zappasodi, P ^a   Rusconi, C ^a   Lazzarino, M ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Deep venous thrombosis; Dexamethasone; Multiple myeloma; Thalidomide therapy

Indexed keywords

DEXAMETHASONE; THALIDOMIDE; THROMBOMODULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; FEMALE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MALE; MYELOMA; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

ADULT; AGED; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MUTATION; THALIDOMIDE; THROMBOMODULIN;

EID: 4444308010     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-0891-6     Document Type: Article

References (15)

1. Cavenagh JD, Oakervee H (2003) Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 120:18-26
2. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323
3. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614-1615
4. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G (2002) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implication for therapy. Blood 100(4):1168-1171
5. Falanga A, Donati MB (2001) Pathogenesis of thrombosis in patients with malignancy. Prog Hematol 73:137-144
6. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G (2002) Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13(13):187-192
7. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G (2003) The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 29(3):275-282
8. Singhal S, Mehta J, Desikan R, Dan Ayers MS, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
9. Camba L, Peccatori J, Pescarollo A, Tresoldi M, Corradini P, Bregni M (2001) Thalidomide and thrombosis in patients with multiple myeloma. Haematologica 86:1108
10. Osman K, Comenzo R, Rajkumar SV (2001) Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344(25):1951-1952
11. Santos AB, Llamas P, Roman A, Prieto E, de Ona R, de Velasco JF, Tomas JF (2003) Evaluation of thrombophilic states in myeloma patients receiving thalidomide: a reasonable doubt. Br J Haematol 122:159-160
12. Kaushal V, Kohli M, Zangari M, Fink L, Metha P (2002) Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol 20(13):3042-3043
13. Esmon CT (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 2644:4743
14. Marchant KK, Comp P (2002) Laboratory issue in diagnosing abnormalities of protein C, thrombomodulin and endothelial cell protein C receptor. Arch Pathol Lab Med 126:1337-1348
15. Ishii H, Uchiyama H, Kazama M (1991) Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65:6118-6125